<DOC>
	<DOCNO>NCT00152399</DOCNO>
	<brief_summary>To assess efficacy safety early administration somatostatin infusion 72 hour plus 2 bolus , compare placebo control acute severe UGIB suspicion PUB .</brief_summary>
	<brief_title>Study Assess Efficacy Safety Somatostatin Treatment Acute Severe Upper Gastrointestinal Bleeding</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Gastrointestinal Hemorrhage</mesh_term>
	<mesh_term>Peptic Ulcer</mesh_term>
	<mesh_term>Peptic Ulcer Hemorrhage</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Male female noncirrhotic patient least 18 year old suspect bleed PU . Patients haematemesis and/or hematochezia and/or melena observe member clinical team ( GP , hospital physician , nurse , ... ) . Either , document sign hypovolemia relate current bleeding episode Or , occurrence symptom hypovolemia Treatment present bleed episode somatostatin analogue , vasoactive drug , endoscopic therapy . Any treatment PPIs ( IV per o ) within last 48 hour precede randomisation . Treatment ( endotherapy pharmacotherapy ) upper gastrointestinal ulcer bleed last 30 day . Deficient haemostasis ( platelet &lt; 40 x 109/l , international normalise ratio prothrombin time &gt; 1.5 ( prothrombin time &lt; 70 % ) , activate partial thromboplastin time &gt; 40 second ( accord normal range validate , local lab ) ) Anticoagulant therapy ( vitamin K antagonist heparin include LMW heparin ) Terminal stage illness endoscopy contraindicate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Peptic ulcer bleeding , upper intestinal bleeding , endoscopy , somatostatin</keyword>
</DOC>